Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection

Drug and Alcohol Dependence

Volumn 101, Issue 3, 2009, Pages 176-182

  Batki, Steven L ^a   Canfield, Kelly M ^b   Smyth, Emily ^b   Ploutz Snyder, Robert ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c UNIVERSITIES SPACE RESEARCH ASSOCIATION   (United States)

Author keywords

Health; Hepatitis C; Methadone; Opioid; Psychiatry; Quality of life; Substance abuse

Indexed keywords

AMPHETAMINE; CANNABIS; COCAINE; METHADONE; OPIATE; PSYCHEDELIC AGENT;

ACCURACY; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CANNABIS ADDICTION; COCAINE DEPENDENCE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SHORT FORM 36;

ADULT; CONTINENTAL POPULATION GROUPS; DEPRESSION; ETHNIC GROUPS; HEALTH STATUS; HEPATITIS C; HUMANS; MENTAL HEALTH; METHADONE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; RANDOM ALLOCATION; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 61849100983     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.12.012     Document Type: Article

References (49)

1. Alberti A., Vario A., Ferrari A., and Pistis R. Review article: chronic hepatitis C-natural history and cofactors. Aliment. Pharmacol. Ther. 22 Suppl. 2 (2005) 74-78
2. Amon J.J., Garfein R.S., Ahdieh-Grant L., Armstrong G., Ouellet L.J., Latka M.H., Vlahov D., Strathdee S.A., Hudson S.M., Kerndt P., des Jarlais D., and Williams I. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin. Infect. Dis. 46 (2008) 1852-1858
3. Beck A.T., and Steer R.A. Beck Anxiety Inventory (1993), The Psychological Corporation, San Antonio, TX
4. Bernstein D., Kleinman L., Barker C.M., Revicki D.A., and Green J. Relationship of health-related quality of life to treatment adherence and sustained virological response in chronic hepatitis C patients. Hepatology 35 (2002) 704-708
5. Brienza R.S., Stein M.D., Chen M., Gogineni A., Sobota M., Maksad J., Hu P., and Clarke J. Depression among needle exchange program and methadone maintenance clients. J. Subst. Abuse Treat. 18 4 (2000) 331-337
6. Bonkovsky H.L., and Woolley J.M. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 29 (1999) 264-270
7. Dan A.A., Martin L.M., Crone C., Ong J.P., Farmer D.W., Wise T., Robbins S.C., and Younossi Z.M. Depression, anemia and health-related quality of life in chronic hepatitis C. J. Hepatol. 44 (2006) 491-498
8. Diaz T., DesJarlais D.C., Vlahov D., Perlis T.E., Edwards V., Friedman S.R., et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am. J. Public Health 91 1 (2001) 23-30
9. Deering D., Frampton C., Horn J., Sellman D., Adamson S., and Potiki T. Health status of clients receiving methadone maintenance treatment using the SF-36 health survey questionnaire. Drug Alcohol Rev. 23 3 (2004) 273-280
10. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W., and Benjamin L. Structural Clinical Interview for DSM-IV Axis I (SCID-I) (1997), American Psychiatric Press, Washington, D.C.
11. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W., and Benjamin L. Structural Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (1997), American Psychiatric Press, Washington, D.C.
12. Fontana R.J., Moyer C.A., Sonnad S., Lok A.S.F., Sneed-Pee N., Walsh J., Klein S., and Webster S. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am. J. Gastroenterol. 96 (2001) 170-178
13. Foster G.R., Goldin R.D., and Thomas H.C. Chronic hepatitis C causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27 (1998) 209-212
14. Gallegos-Orozco J.F., Fuentes A.P., Gerardo Arqueta J., Perez-Pruna C., Hinojosa-Becerril C., Sixtos-Alonso M.S., Cruz-Castellanos S., Gutierrez-Reyes G., Olivera-Martinez M.A., Gutierrez-Ruiz M.C., and Kershenobich D. Health-related quality of life and depression in patients with chronic hepatitis C. Arch. Med. Res. 34 2 (2003) 124-129
15. Garfein R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., and Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18 Suppl. 1 (1998) S11-S19
16. Garfein R.S., Vlahov D., Galai N., Doherty M.C., and Nelson K.E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, and human immunodeficiency, and human T-lymphotrophic viruses. Am. J. Public Health 86 5 (1996) 655-661
17. Gjeruldsen S., Loge J.H., Myrvang B., and Opjordsmoen S. Drug addiction in hepatitis C patients leads to a lower quality of life. Nord. J. Psychiatry 60 2 (2006) 157-161
18. Golden J., O'Dwyer A.M., and Conroy R.M. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen. Hosp. Psychiatry 27 (2005) 431-438
19. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., Busch M.P., Tobler L.H., Phelps B., and Moss A.R. Hepatitis C virus seroconversion among young injection srug users: relationships and risks. J. Infect. Dis. 186 (2002) 1558-1564
20. Hahn J.A., Page-Shafer K., Lum P., Ochoa K., and Moss A.R. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 34 (2001) 180-187
21. Hagan H., DesJarlais D.C., Stern R., Lelutiu-weinberger C., Scheinmann R., Stauss S., and Flom P.L. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int. J. Drug Policy 18 (2007) 341-351
22. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., and Alexander E.R. Sharing of drug preparation equipment a risk factor for hepatitis C. Am. J. Public Health 91 (2001) 42-46
23. Hauser W., Zimmer C., Schiedermaier P., and Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom. Med. 66 (2004) 954-958
24. Hussain K.B., Fontana R.J., Moyer C.A., Su G.L., Sneed-Pee N., and Lok A.S. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am. J. Gastroenterol. 96 9 (2001) 2737-2744
25. Kallman J., ONeil M.M., Larive B., Boparai N., Calabrese L., and Younossi Z.M. Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection. Dig. Dis. Sci. 52 10 (2007) 2531-2539
26. Lim J.K., Cronkite R., Goldstein M.K., and Cheung R.C. The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. J. Clin. Gastroenterol. 40 6 (2006) 528-534
27. Mason B.J., Kocsis J.H., Melia D., Khuri E.T., Sweeney J., Wells A., Borg L., Millman R.B., and Kreek M.J. Psychiatric comorbidity in methadone maintained patients. J. Addict. Dis. 17 3 (1998) 75-89
28. McHutchison J.G., Ware Jr. J.E., Bayliss M.S., Planko S., Albrecht J.K., Cort S., Yang I., and Neary M.P. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. Hepatitis Interventional Therapy Group. J. Hepatol. 34 (2001) 140-147
29. McLellan A.T., Cacciola J.S., and Zanis D. The Addiction Severity Index-"Lite" (ASI-"Lite") (1997), Center for the Studies of Addiction, University of Pennsylvania, Philadelphia VA Medical Center
30. Miller E.R., Hiller J.E., and Shaw D.R. Quality of life in HCV-infection: Lack of association with ALT levels. Aust. N. Z. J. Public Health 25 4 (2001) 355-361
31. Millson P., Challacombe L., Villeneuve P.J., Strike C.J., Fischer B., Myers T., Shore R., and Hopkins S. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Eur. Addict. Res. 12 (2006) 74-82
32. Neary M.P., Cort S., Bayliss M.S., and Ware Jr. J.E. Sustained virological response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Sem. Liver Dis. 19 Suppl. 1 (1999) 77-85
33. Perez J.F., Farrington L.A., Pecorano C., Hutin Y.J.F., and Armstrong G.L. Estimated global prevalence of hepatitis C virus infection. 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA, September 30-October 3 (2004)
34. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 34 (2001) 730-739
35. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group (IHIT). Lancet 352 9138 (1998) 1426-1432
36. Rasenack J., Zeuzem S., Feinman S.V., Heathcote E.J., Manns M., Yoshida E.M., Swain M.G., Gane E., Diago M., Revicki D.A., Lin A., Wintfeld N., and Green J. Peginterferon alpha-2a (40 kD) [Pegysis] improves HRQOL outcomes compared with unmodified interferon alpha-2a [Roferon-A] in patients with chronic hepatitis C. Pharmacoeconomics 21 (2003) 341-349
37. Rowan P.J., Al-Jurdi R., Tavakoli-Tabasi S., Kunik M.E., Satrom S.L., and El-Serag H.B. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J. Clin. Gastroenterol. 39 8 (2005) 731-736
38. Ryan C.F., and White J.M. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction 91 (1996) 39-45
39. Shepard C.W., Finelli L., and Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
40. Spiegel B.M., Younossi Z.M., Hays R.D., Revicki D., Robbins S., and Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41 4 (2005) 790-800
41. Stein M.D., Mulvey K.P., Plough A., and Samet J.H. The functioning and well being of persons who seek treatment for drug and alcohol use. J. Subst. Abuse 10 1 (1998) 75-84
42. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. American association for the study of liver diseases. Diagn. Manage. Treat. Hepat. C: Hepatol. 39 4 (2004) 1147-1171
43. Thorpe L., Ouellet L., Hershow R., Bailey S., Williams I., and Monterosso E. The mulitperson use of non-syringe injection equipment and risk of hepatitis C infection in a cohort of young adult injection drug users, Chicago 1997-1999. Ann. Epidemiol. 10 (2000) 472-473
44. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., Monterroso E.R., and Garfein R.S. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am. J. Epidemiol. 155 (2002) 645-653
45. vanBeek I., Dwyer R., Dore G.J., Luo K., and Kaldor J.M. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 317 (1998) 433-437
46. Villano S.A., Vlahov D., Nelson K.E., Lyles C.M., Cohn S., and Thomas D.L. Incidence and risk factors for hepatitis C among injection drug users in Baltimore. Maryland. Clinical Microbiology. 35 12 (1997) 3274-3277
47. Ware J.E., and Kosinski M. SF-36 Physical and Mental Health Summary Scales: A Manual for Users Version 1. Second Edition (2001), Quality Metric Incorporated, Lincoln, RI
48. Ware J.E., Kosinski M., and Gandek B. SF-36 Health Survey: Manual & Interpretation Guide (2000), Quality Metric Incorporated, Lincoln, RI
49. Younossi Z., Kallman J., and Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 45 3 (2007) 806-816